<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute pericarditis: Treatment and prognosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute pericarditis: Treatment and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute pericarditis: Treatment and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Massimo Imazio, MD, FESC, FHFA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin M LeWinter, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H24417202"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The pericardium is a fibroelastic sac made up of visceral and parietal layers separated by a (potential) space, the pericardial cavity. In healthy individuals, the pericardial cavity contains 15 to 50 mL of an ultrafiltrate of plasma.</p><p>Diseases of the pericardium present clinically in one of several ways:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute and recurrent pericarditis</p><p class="bulletIndent1"><span class="glyph">●</span>Pericardial effusion without major hemodynamic compromise</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac tamponade</p><p class="bulletIndent1"><span class="glyph">●</span>Constrictive pericarditis</p><p class="bulletIndent1"><span class="glyph">●</span>Effusive-constrictive pericarditis</p><p></p><p>Acute pericarditis refers to inflammation of the pericardial sac. The term myopericarditis, or perimyocarditis, is used for cases of acute pericarditis that also demonstrate myocardial inflammation; myopericarditis is used for cases with predominant pericarditis and normal ventricular function, and perimyocarditis is used for cases with predominant myocarditis and/or ventricular dysfunction (ie, new wall motion abnormalities or reduced left ventricular ejection fraction). (See  <a class="medical medical_review" href="/d/html/4930.html" rel="external">"Myopericarditis"</a>.)</p><p>The treatment and prognosis of acute pericarditis will be reviewed here. The etiology, clinical presentation, and diagnostic evaluation of acute pericarditis and other pericardial disease processes are discussed separately. (See  <a class="medical medical_review" href="/d/html/4957.html" rel="external">"Etiology of pericardial disease"</a> and  <a class="medical medical_review" href="/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/4944.html" rel="external">"Recurrent pericarditis"</a> and  <a class="medical medical_review" href="/d/html/4930.html" rel="external">"Myopericarditis"</a> and  <a class="medical medical_review" href="/d/html/4921.html" rel="external">"Cardiac tamponade"</a> and  <a class="medical medical_review" href="/d/html/4938.html" rel="external">"Constrictive pericarditis: Diagnostic evaluation"</a> and  <a class="medical medical_review" href="/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis"</a>.)</p><p class="headingAnchor" id="H12602665"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The therapy of acute pericarditis should be targeted as much as possible to the underlying etiology  (<a class="graphic graphic_table graphicRef60949" href="/d/graphic/60949.html" rel="external">table 1</a>) [<a href="#rid1">1-5</a>]. However, in resource-abundant countries, most cases of acute pericarditis in immunocompetent patients are due to viral infection or are idiopathic; it is generally assumed that most cases of "idiopathic" pericarditis are viral in etiology. Because of the relatively benign course associated with the most common causes of pericarditis (&gt;80 percent of cases), it is not necessary to search for the etiology in all patients. As such, most patients are treated for a presumptive viral cause with nonsteroidal antiinflammatory drugs (NSAIDs) and <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>. (See  <a class="medical medical_review" href="/d/html/4954.html" rel="external">"Pericardial disease associated with cancer: Clinical presentation and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/8002.html" rel="external">"Tuberculous pericarditis"</a> and  <a class="medical medical_review" href="/d/html/2128.html" rel="external">"Purulent pericarditis"</a>.) </p><p>In acute viral or idiopathic pericarditis, no therapy has been rigorously proven to prevent serious sequelae, such as cardiac tamponade and constrictive pericarditis. Fortunately, however, these complications are rare [<a href="#rid6">6,7</a>]. (See  <a class="medical medical_review" href="/d/html/4938.html" rel="external">"Constrictive pericarditis: Diagnostic evaluation"</a> and  <a class="medical medical_review" href="/d/html/4921.html" rel="external">"Cardiac tamponade"</a>.)</p><p class="headingAnchor" id="H439961613"><span class="h2">General approach to treatment</span><span class="headingEndMark"> — </span>In the treatment of acute pericarditis, the goals of therapy are the relief of pain, resolution of inflammation (and, if present, pericardial effusion), and the prevention of recurrence. Our general approach to treatment is as follows  (<a class="graphic graphic_algorithm graphicRef114845" href="/d/graphic/114845.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ambulatory versus inpatient treatment</strong> – Most low-risk patients with acute pericarditis can be managed effectively in an ambulatory setting, while high-risk patients should be admitted to initiate treatment and continue the diagnostic evaluation. (See <a class="local">'Which patients require hospitalization?'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Activity restriction</strong> – Patients should be instructed to restrict strenuous physical activity until symptoms have resolved and biomarkers have normalized. (See <a class="local">'Activity restriction'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For nearly all patients with acute idiopathic or viral pericarditis, we recommend combination therapy with <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> plus NSAIDs. (See <a class="local">'Nonsteroidal antiinflammatory drugs'</a> below and <a class="local">'Colchicine'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with an identified cause other than viral infection, specific therapy appropriate to the underlying disorder is indicated.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Glucocorticoids should be used for initial treatment of acute pericarditis only in patients with contraindications to NSAIDs (eg, renal failure or pregnancy at ≥20 weeks gestation), or for specific indications (eg, systemic inflammatory diseases), and should be used at the lowest effective dose. (See <a class="local">'Glucocorticoids'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tapering treatment</strong> – Following the resolution of symptoms, we taper the dose of the antiinflammatory agent weekly in an attempt to reduce the subsequent recurrence rate. <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">Colchicine</a> is continued for a total duration of three months. (See <a class="local">'NSAID dosing'</a> below and <a class="local">'Glucocorticoid dosing'</a> below and <a class="local">'Colchicine dosing'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory or recurrent symptoms</strong> – Most patients whose symptoms worsen or recur following the initial course of therapy can still be managed effectively with medical therapy alone, and outpatient management remains feasible in almost all cases. (See  <a class="medical medical_review" href="/d/html/4944.html" rel="external">"Recurrent pericarditis"</a>.)</p><p></p><p class="headingAnchor" id="H3118623461"><span class="h2">Which patients require hospitalization?</span><span class="headingEndMark"> — </span>High-risk patients with acute pericarditis  (<a class="graphic graphic_algorithm graphicRef114845" href="/d/graphic/114845.html" rel="external">algorithm 1</a>) should be admitted to the hospital in order to initiate appropriate therapy and expedite a thorough initial evaluation. Conversely, patients with uncomplicated (ie, low-risk) acute pericarditis can usually be evaluated and sent home, with outpatient follow-up to assess the efficacy of treatment.</p><p>Features of acute pericarditis associated with a higher risk include [<a href="#rid8">8,9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Fever (&gt;38°C [100.4°F])</p><p class="bulletIndent1"><span class="glyph">●</span>Subacute course (without acute onset of chest pain)</p><p class="bulletIndent1"><span class="glyph">●</span>Evidence suggesting cardiac tamponade (eg, hemodynamic compromise) (see  <a class="medical medical_review" href="/d/html/4921.html" rel="external">"Cardiac tamponade"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>A large pericardial effusion (ie, an end-diastolic echo-free space of more than 20 mm)</p><p class="bulletIndent1"><span class="glyph">●</span>Immunosuppression and immunodepressed patients</p><p class="bulletIndent1"><span class="glyph">●</span>Anticoagulant use (eg, vitamin K antagonists [eg, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>] or novel oral anticoagulants)</p><p class="bulletIndent1"><span class="glyph">●</span>Acute trauma</p><p class="bulletIndent1"><span class="glyph">●</span>Failure to show clinical improvement following seven days of appropriately dosed NSAID and <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated cardiac troponin, which suggests myopericarditis/perimyocarditis</p><p></p><p>Patients with none of these high-risk features can be safely treated on an outpatient basis  (<a class="graphic graphic_algorithm graphicRef114845" href="/d/graphic/114845.html" rel="external">algorithm 1</a>). A full discussion of risk assessment and determining the need for hospitalization is presented separately. (See  <a class="medical medical_review" href="/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis", section on 'Assessment of risk and need for hospitalization'</a>.)</p><p class="headingAnchor" id="H2234623"><span class="h2">Activity restriction</span><span class="headingEndMark"> — </span>Strenuous physical activity may trigger recurrence of symptoms; therefore, such activity should be avoided until symptom resolution and normalization of biomarkers. While there are little systematic data to guide recommendations on activity restriction, our experts' approach to activity restriction is consistent with the advice of professional societies [<a href="#rid10">10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Noncompetitive athletes should restrict activity until the resolution of symptoms and normalization of biomarkers (this approach has been endorsed by the 2015 ESC guidelines) [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Competitive athletes should not participate in competitive sports for at least three months following the resolution of symptoms and normalization of biomarkers, and should be re-evaluated by a clinician prior to resuming training and competition. In patients with milder symptoms which promptly resolve with treatment, a shorter period or activity restriction (a minimum of one month) may be reasonable on a case-by-case basis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In cases of myopericarditis or perimyocarditis, we recommend withdrawal from competitive sports for six months and return to play only after normalization of laboratory data (eg, markers of inflammation, electrocardiogram [ECG], and echocardiogram). (See  <a class="medical medical_review" href="/d/html/4930.html" rel="external">"Myopericarditis", section on 'Treatment'</a>.)</p><p></p><p class="headingAnchor" id="H1490671301"><span class="h2">Medical therapies</span></p><p class="headingAnchor" id="H12602672"><span class="h3">Nonsteroidal antiinflammatory drugs</span><span class="headingEndMark"> — </span>For nearly all patients with acute idiopathic or viral pericarditis, we recommend NSAIDs (in combination with <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>) as the initial treatment  (<a class="graphic graphic_algorithm graphicRef114845" href="/d/graphic/114845.html" rel="external">algorithm 1</a>). There are two approaches to determine the duration of NSAID therapy and the proper time to begin tapering treatment; long-term data demonstrating superiority of one method over the other are not available.</p><p class="bulletIndent1"><span class="glyph">●</span>Duration of treatment is based upon the resolution of symptoms, which usually occurs in two weeks or less, with tapering once the patient is symptom-free for at least 24 hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Duration of treatment is based upon the resolution of symptoms <strong>and</strong> normalization of C-reactive protein (CRP). In this approach, CRP is assessed at presentation and then weekly, using the antiinflammatory dose of NSAIDs until complete resolution of symptoms (for at least 24 hours) and normalization of CRP, at which point tapering begins [<a href="#rid12">12</a>].</p><p></p><p>Failure to respond to <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> or NSAID therapy within one week (defined as persistence of fever, pleuritic chest pain, a new pericardial effusion, or worsening of general illness) suggests that a cause other than idiopathic or viral pericarditis is present. In such instances, a thorough search for the etiology should be performed. To expedite the diagnostic evaluation and for symptom control, some patients may require admission to the hospital. The main causes to be ruled out include tuberculous or other bacterial forms of pericarditis, cancer (especially lung cancer, breast cancer, and lymphomas and leukemias), post-cardiac injury syndromes, and systemic inflammatory diseases. (See  <a class="medical medical_review" href="/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis", section on 'Establishing a definite etiology'</a>.)</p><p>Based on the results of multiple cohort studies and one randomized study, treatment with an antiinflammatory dose of NSAIDs alone appears to be effective in approximately 70 to 80 percent of pericarditis cases presumed to be of viral or idiopathic origin [<a href="#rid7">7,8,13</a>]. Primary therapy has been the administration of oral NSAIDs, particularly <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> or <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>; <a class="drug drug_general" data-topicid="8591" href="/d/drug information/8591.html" rel="external">ketorolac</a>, a parenteral NSAID, is also effective  (<a class="graphic graphic_table graphicRef56484" href="/d/graphic/56484.html" rel="external">table 2</a>) [<a href="#rid14">14</a>]. NSAIDs (including aspirin) function to both reduce inflammation and relieve pain in most patients [<a href="#rid7">7,8,13,15-17</a>]. Despite these benefits, however, there is no evidence that NSAIDs alter the natural history of acute pericarditis.</p><p>In a series of 254 patients deemed to be at low risk who were treated with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> as outpatients, 98 percent of patients who responded to aspirin were presumed to have idiopathic or viral disease, while 2 percent of the patients who responded to aspirin were subsequently diagnosed with an autoimmune disorder [<a href="#rid8">8</a>]. By contrast, among the patients who did not respond to aspirin after seven days, only 39 percent were deemed idiopathic, while 43 percent were diagnosed with an autoimmune disorder and 18 percent with tuberculous pericarditis. At follow-up, aspirin resistance was associated with significant increases in the rates of recurrent pericarditis (61 versus 10 percent) and constrictive pericarditis (9 versus 1 percent).</p><p>A theoretical concern is that the antiplatelet activity of <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (or another NSAID) might promote the development of a hemorrhagic pericardial effusion. However, such a relationship has never been convincingly established, and the risk-benefit ratio seems to favor the use of these drugs. (See <a class="local">'Bleeding risk of NSAIDs combined with other antithrombotics'</a> below.)</p><p class="headingAnchor" id="H12602679"><span class="h4">NSAID dosing</span><span class="headingEndMark"> — </span>We agree with the 2015 ESC guidelines, which recommended the use of an NSAID for the treatment of acute pericarditis [<a href="#rid11">11</a>]. One of the following NSAID regimens is commonly used  (<a class="graphic graphic_table graphicRef56484" href="/d/graphic/56484.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ibuprofen</strong><strong> </strong>– The <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> dose is 600 to 800 mg three times per day  (<a class="graphic graphic_table graphicRef56484" href="/d/graphic/56484.html" rel="external">table 2</a>). Following the resolution of symptoms, we taper the ibuprofen dose weekly in an attempt to reduce the subsequent recurrence rate [<a href="#rid8">8,18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aspirin</strong><strong> </strong>– The <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> dose is 650 to 1000 mg three times per day  (<a class="graphic graphic_table graphicRef56484" href="/d/graphic/56484.html" rel="external">table 2</a>). Following the resolution of symptoms, we taper the aspirin dose weekly in an attempt to reduce the subsequent recurrence rate [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indomethacin</strong><strong> </strong>– The <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> dose is 25 to 50 mg three times per day  (<a class="graphic graphic_table graphicRef56484" href="/d/graphic/56484.html" rel="external">table 2</a>). Following the resolution of symptoms, we taper the indomethacin dose weekly in an attempt to reduce the subsequent recurrence rate [<a href="#rid8">8,18</a>]. Indomethacin is associated with more side effects, and it is usually considered for recurrences. (See  <a class="medical medical_review" href="/d/html/4944.html" rel="external">"Recurrent pericarditis", section on 'NSAID or aspirin'</a>.)</p><p></p><p>Any of the listed NSAIDs can be continued for days or weeks, if necessary, for recurrent or incessant attacks. (See  <a class="medical medical_review" href="/d/html/4944.html" rel="external">"Recurrent pericarditis", section on 'NSAID or aspirin'</a>.)</p><p>In symptomatic pericarditis occurring within days after an acute myocardial infarction, we suggest <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> plus <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> rather than another NSAID plus colchicine. The use of NSAIDs other than aspirin should be <strong>avoided</strong>, since antiinflammatory therapy may impair scar formation [<a href="#rid19">19</a>]. Aspirin may also be the first choice in patients who require concomitant antiplatelet therapy for any reason. With either regimen, gastrointestinal protection should be provided. (See  <a class="medical medical_review" href="/d/html/4937.html" rel="external">"Pericardial complications of myocardial infarction"</a> and  <a class="medical medical_review" href="/d/html/35.html" rel="external">"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity"</a> and <a class="local">'Gastrointestinal protection'</a> below.)</p><p class="headingAnchor" id="H1410687"><span class="h4">Gastrointestinal protection</span><span class="headingEndMark"> — </span>NSAIDs can lead to gastrointestinal toxicity (ie, gastritis, ulcers, etc), particularly when used in high doses or for prolonged periods of time. In addition to high doses or prolonged periods of treatment, patient-related factors associated with a higher risk of gastrointestinal toxicity include:</p><p class="bulletIndent1"><span class="glyph">●</span>History of peptic ulcer disease</p><p class="bulletIndent1"><span class="glyph">●</span>Age greater than 65 years</p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent use of <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, corticosteroids, or anticoagulants</p><p></p><p>Patients considered at risk of gastrointestinal toxicity related to NSAID treatment should be treated with NSAIDs for the shortest interval possible and receive concomitant gastroprotective therapy while taking NSAIDs. Proton pump inhibitors (eg, <a class="drug drug_general" data-topicid="9718" href="/d/drug information/9718.html" rel="external">omeprazole</a>, <a class="drug drug_general" data-topicid="9474" href="/d/drug information/9474.html" rel="external">pantoprazole</a>) are generally preferred for prevention of gastrointestinal toxicity due to their efficacy and favorable safety profile. (See  <a class="medical medical_review" href="/d/html/35.html" rel="external">"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity"</a>.)</p><p class="headingAnchor" id="H13331166"><span class="h4">Bleeding risk of NSAIDs combined with other antithrombotics</span><span class="headingEndMark"> — </span>In patients who require more than one antiplatelet or anticoagulant as therapy for an underlying condition, there is a greater risk of bleeding complications. On occasion, patients with acute pericarditis treated with NSAIDs may also have an indication for an additional antiplatelet or anticoagulant, in which case the overall risk of bleeding should be assessed. Because NSAIDs (especially <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>) can impact the metabolism of vitamin K antagonists, patients will typically require close monitoring and dose adjustments for the duration of treatment for acute pericarditis. (See  <a class="medical medical_review" href="/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Mitigating bleeding risk'</a> and  <a class="medical medical_review" href="/d/html/1337.html" rel="external">"Biology of warfarin and modulators of INR control", section on 'Aspirin/NSAIDs'</a>.)</p><p>In patients who require antiplatelet therapy for another indication (eg, following coronary stenting), there are no specific contraindications or additional risks of bleeding when NSAIDs are used during acute pericarditis. In this setting, however, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> is generally the first choice to treat pericarditis, but doses should be increased to reach antiinflammatory effects (from 100 to 300 mg to up to 650 to 1000 mg three times per day). (See <a class="local">'NSAID dosing'</a> above.)</p><p>Concomitant use of heparin and anticoagulant therapies is often perceived as a possible risk factor for the development of a worsening or hemorrhagic pericardial effusion that may result in cardiac tamponade, but the available evidence does not support this [<a href="#rid20">20</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>An analysis of 453 consecutive cases of acute pericarditis did not show a higher risk of hemorrhagic effusion in patients on antithrombotics [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study of 274 patients with acute pericarditis or myopericarditis, the use of heparin or other anticoagulants was not associated with an increased risk of cardiac tamponade (odds ratio [OR] 1.1, 95% CI 0.3-3.5) [<a href="#rid21">21</a>].</p><p></p><p>NSAIDs (including <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>) alter the metabolism of vitamin K antagonists (eg, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>), thus enhancing the anticoagulant effect. Consequently, careful monitoring and frequent dose adjustment are needed. Additionally, consideration should be given to using alternative antiinflammatory options, such as glucocorticoids. Although glucocorticoids have the potential for fewer bleeding-related drug interactions in patients requiring both antiinflammatory drugs and chronic anticoagulation therapy, the potential benefits of reduced risk of bleeding should be weighed against potential side effects and a higher rate of recurrent pericarditis associated with glucocorticoids. Because of these glucocorticoid concerns, we generally prefer therapy with NSAIDs, with additional monitoring for drug interactions and bleeding complications. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p>There are no significant reported interactions between NSAIDs or other antiplatelet therapies and <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H12602686"><span class="h3">Colchicine</span><span class="headingEndMark"> — </span>For all patients with acute idiopathic or viral pericarditis  (<a class="graphic graphic_algorithm graphicRef114845" href="/d/graphic/114845.html" rel="external">algorithm 1</a>), we recommend that <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> be added to antiinflammatory therapy (either NSAIDs or glucocorticoids)  (<a class="graphic graphic_table graphicRef56484" href="/d/graphic/56484.html" rel="external">table 2</a>) [<a href="#rid11">11,23</a>]. Additionally, colchicine is generally efficacious for pericarditis caused by systemic inflammatory diseases and post-cardiac injury syndromes. However, for patients with diagnosed bacterial pericarditis, colchicine has not been proven efficacious and, on the contrary, may theoretically impair the clearance of the infectious agent. Colchicine is also not proven to be efficacious in malignancy-related pericarditis and pericardial effusion.</p><p><a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">Colchicine</a>, when used as an adjunct to NSAID therapy, reduces symptoms, decreases the rate of recurrent pericarditis, and is generally well tolerated. The 2015 ESC guidelines concluded that the weight of evidence supported the efficacy of colchicine, alone or in combination with NSAIDs, in the treatment of acute pericarditis [<a href="#rid11">11</a>]. Of note, colchicine is not approved for the prevention of recurrent pericarditis in North America and most European countries (as of 2019, it is approved for this indication in Italy and Austria), as such its use is off-label. (See  <a class="medical medical_review" href="/d/html/4944.html" rel="external">"Recurrent pericarditis", section on 'Colchicine'</a>.)</p><p>The efficacy of <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> in the primary management of acute pericarditis has been evaluated in randomized trials:</p><p class="bulletIndent1"><span class="glyph">●</span>In the ICAP trial, a randomized, double-blind study of <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> versus placebo in addition to standard antiinflammatory therapy for treatment of a first episode of acute pericarditis (77 percent idiopathic) in 240 patients, colchicine added to standard antiinflammatory therapy significantly reduced the risk of recurrence (17 versus 38 percent with antiinflammatory therapy alone; relative risk reduction 0.56, 95% CI 0.30-0.72) [<a href="#rid24">24</a>]. In addition, colchicine added to antiinflammatory treatment resulted in significantly better rates of remission and fewer hospitalizations compared with antiinflammatory treatment alone. No serious adverse events were observed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the open label COPE trial of 120 patients with a first episode of acute pericarditis (84 percent idiopathic), the recurrence rate of pericarditis within 18 months was significantly lower in the <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> plus <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> group (11 versus 32 percent with aspirin alone; number needed to treat to prevent one recurrence equals five) [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a later open-label trial in 110 patients with a first episode of acute idiopathic pericarditis, the addition of <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> to conventional antiinflammatory treatment did not reduce the recurrence rate [<a href="#rid25">25</a>]. However, the study has important limitations to be acknowledged (eg, probably underpowered to test colchicine efficacy, diagnostic criteria for pericarditis not consistent with 2015 ESC guidelines, and possible significant delay in the administration of colchicine from symptoms onset) that may limit its clinical applicability [<a href="#rid26">26</a>].</p><p></p><p>In the COPE and ICAP studies, adult patients were excluded if they had elevated levels of aminotransferases, creatinine, or troponin and liver diseases, myopathy, blood dyscrasias, or inflammatory bowel disease. Pregnant or lactating women were also excluded as well as patients with bacterial or neoplastic pericarditis.</p><p>The efficacy of <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> in the treatment of pericarditis has also been assessed in several systematic reviews and meta-analyses (which include patients with both acute and recurrent pericarditis) [<a href="#rid27">27-30</a>]. In a 2014 systematic review and meta-analysis, which included four randomized, double-blind trials (564 patients) of colchicine for both initial and recurrent episodes of pericarditis, colchicine use was associated with a reduced risk of recurrent pericarditis at 18 months in patients being treated for acute (hazard ratio [HR] 0.40, 95% CI 0.27-0.61) or recurrent (HR 0.37, 95% CI 0.24-0.58) pericarditis [<a href="#rid28">28</a>]. There was no significant increase in adverse effects related to colchicine therapy [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/d/html/4944.html" rel="external">"Recurrent pericarditis", section on 'Colchicine'</a>.)</p><p class="headingAnchor" id="H409429724"><span class="h4">Colchicine dosing</span><span class="headingEndMark"> — </span>The 0.5 mg dose of <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> is not available in many countries, including the United States and Canada where 0.6 mg tablets are used empirically in place of 0.5 mg tablets.</p><p><a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">Colchicine</a> may be given with or without a loading dose. When a loading dose is chosen, the loading dose is typically 0.5 to 1 mg (or 0.6 to 1.2 mg) twice daily on day 1, depending upon the patient’s body weight.</p><p>The daily maintenance dose of <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> is weight-based:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients weighing ≥70 kg should receive 0.5 to 0.6 mg twice daily</p><p class="bulletIndent1"><span class="glyph">●</span>Patients weighing &lt;70 kg should receive 0.5 to 0.6 mg once daily</p><p></p><p><a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">Colchicine</a> should be administered for a total of three months for patients with an initial episode of acute pericarditis. In ICAP, colchicine was given without a loading dose as 0.5 mg twice daily for three months for patients weighing &gt;70 kg or 0.5 mg once daily for patients weighing ≤70 kg.</p><p class="headingAnchor" id="H2166278999"><span class="h4">Colchicine side effects</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">Colchicine</a> is typically well tolerated. Side effects, most commonly gastrointestinal (eg, diarrhea, nausea, vomiting), are uncommon at low doses (0.5 to 1.2 mg per day), even when given continuously over years. Less common (&lt;1 percent) side effects include bone marrow suppression, hepatotoxicity, and myotoxicity. Chronic renal insufficiency leading to increased colchicine levels appears to be the major risk factor for side effects and other possible negative interactions. In addition, colchicine has drug interactions and altered metabolism in certain patient populations. </p><p class="headingAnchor" id="H12602693"><span class="h3">Glucocorticoids</span><span class="headingEndMark"> — </span>Glucocorticoids should be used for initial treatment of acute pericarditis only in patients with contraindications to NSAIDs (eg, renal failure or pregnancy at ≥20 weeks gestation), or for specific indications (eg, systemic inflammatory diseases), and should be used at the lowest effective dose. The number of such patients requiring glucocorticoids should be quite low (10 percent or less), as illustrated in two studies by an almost 90 percent response rate to <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> alone within seven days, with most of the nonresponders having an autoimmune disease or tuberculosis [<a href="#rid8">8,13</a>]. Glucocorticoids may also be used in the event of failed initial therapy with aspirin/NSAID plus <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>, suggesting recurrent or refractory pericarditis. (See  <a class="medical medical_review" href="/d/html/4944.html" rel="external">"Recurrent pericarditis"</a>.)</p><p>Limited data are available on the efficacy of glucocorticoid therapy for acute pericarditis, as such therapy is generally limited to patients with nonresponse or contraindications to NSAID use [<a href="#rid25">25</a>]. Observational studies suggest that glucocorticoid therapy early in the course of the disease is more likely to be associated with recurrent episodes [<a href="#rid13">13,31-33</a>]. The best data come from the COPE trial of <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> therapy in which glucocorticoids were given only when <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> was contraindicated or not tolerated [<a href="#rid13">13</a>]. Glucocorticoid use was a significant predictor of recurrence (OR 4.30, 95% CI 1.21-15.25). The same effect has been reported for patients with the first recurrence or multiple recurrences and may be due to promotion of viral replication [<a href="#rid31">31,34-36</a>]. In a subsequent systematic review which included two randomized trials comparing steroid therapy with standard NSAID therapy and one trial of low-dose versus high-dose steroid therapy (with or without other therapy with NSAIDs or colchicine), the administration of steroids was associated with a trend toward a higher rate of recurrent pericarditis (OR 7.50, 95% CI 0.62-90.65) [<a href="#rid37">37</a>].</p><p>In addition to concerns about the efficacy of glucocorticoid therapy as initial treatment of acute pericarditis, chronic use of systemic glucocorticoids is associated with a number of potentially significant side effects. As such, when glucocorticoids are required, they should be given at the lowest appropriate and effective dose. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p class="headingAnchor" id="H6865888"><span class="h4">Glucocorticoid dosing</span><span class="headingEndMark"> — </span>While NSAIDs and <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> remain the preferred treatment options for acute pericarditis, a minority of patients will have refractory symptoms requiring treatment with systemic steroid therapy. There are conflicting data, mostly derived from observational studies, regarding the optimal dosing and tapering of steroid therapy when used to treat pericarditis.</p><p class="headingAnchor" id="H6865918"><span class="h5">Our approach to glucocorticoid dosing</span><span class="headingEndMark"> — </span>For patients who require glucocorticoid therapy for acute pericarditis, we suggest the use of moderate initial dosing (eg, 0.2 to 0.5 mg/kg/day of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>) followed by a slow taper  (<a class="graphic graphic_table graphicRef56484" href="/d/graphic/56484.html" rel="external">table 2</a>) rather than high doses with a rapid taper. We add <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> during glucocorticoid therapy and continue colchicine for three months for initial cases of acute pericarditis and six months in recurrent cases. We introduce <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> or another NSAID toward the end of tapering or in case of recurrences instead of increasing the dose of the glucocorticoids. (See  <a class="medical medical_review" href="/d/html/4944.html" rel="external">"Recurrent pericarditis"</a>.)</p><p>Results from a study of patients with recurrent pericarditis suggest that lower glucocorticoid doses may also be feasible in acute pericarditis, although these populations differ. In an observational study, 100 patients with recurrent pericarditis were treated with glucocorticoids (51 with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 1 mg/kg/day and 49 with prednisone 0.2 to 0.5 mg/kg/day) [<a href="#rid38">38</a>]. After adjustment for potential confounders, only high doses of prednisone were associated with more side effects, recurrences, and hospitalizations (HR 3.61, 95% CI 1.96-6.63). In a systematic review of published studies on medical therapy for pericarditis, data from three observational studies of steroid treatment showed that steroid use was associated with a trend toward increased risk of recurrent pericarditis (OR 7.50, 95% CI 0.62-90.65) [<a href="#rid37">37</a>]. However, low-dose steroids were superior to high-dose steroids for treatment failure or recurrent pericarditis (OR 0.29, 95% CI 0.13-0.66), rehospitalization for pericarditis (OR 0.19, 95% CI 0.06-0.63), and adverse effects (OR 0.07, 95% CI 0.01-0.54).</p><p>In our experience, rapid tapering of systemic glucocorticoids increases the risk of treatment failure and recurrence. Although high doses of glucocorticoids (eg, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 1 mg/kg/day) have been recommended in the ESC guidelines, use of lower doses (eg, prednisone 0.2 to 0.5 mg/kg/day) may be equally efficacious [<a href="#rid11">11</a>]. These lower doses may be useful in reducing the risk of steroid side effects, which have been reported in up to 25 percent of patients treated with high doses. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p>We usually begin tapering glucocorticoids at two to four weeks after resolution of symptoms and CRP normalization. Each decrement in <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> dose should proceed only if the patient is asymptomatic and CRP remains normalized, particularly for doses lower than 25 mg/day. A proposed tapering scheme follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Daily dose &gt;50 mg – Taper 10 mg/day every one to two weeks</p><p class="bulletIndent1"><span class="glyph">●</span>Daily dose 25 to 50 mg – Taper 5 to 10 mg/day every one to two weeks</p><p class="bulletIndent1"><span class="glyph">●</span>Daily dose 15 to 25 mg – Taper 2.5 mg/day every two to four weeks</p><p class="bulletIndent1"><span class="glyph">●</span>Daily dose &lt;15 mg – Taper 1.25 to 2.5 mg/day every two to six weeks</p><p></p><p class="headingAnchor" id="H4140666083"><span class="h5">Other approaches</span><span class="headingEndMark"> — </span>The 2015 ESC guidelines recommended that systemic steroid therapy be restricted to patients with the following conditions [<a href="#rid11">11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with symptoms refractory to standard therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Acute pericarditis due to connective tissue disease</p><p class="bulletIndent1"><span class="glyph">●</span>Uremic pericarditis </p><p></p><p>The 2015 ESC guidelines recommend use of low to moderate doses of glucocorticoids (eg, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 0.2 to 0.5 mg/kg/day) when indicated. In contrast to our suggestions, the ESC guidelines recommend rapid tapering to reduce the risk of systemic side effects [<a href="#rid11">11,37</a>]. In patients with a coexisting pericardial effusion, intrapericardial steroid administration is an option that limits systemic toxicity [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H12604886"><span class="h2">Adjunctive therapies</span><span class="headingEndMark"> — </span>Most patients with uncomplicated low risk acute pericarditis are managed effectively with medical therapy alone. On occasion, however, patients with pericarditis may require adjunctive therapies for:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with elevated heart rate (eg, heart rate &gt;70 to 75 beats per minute), no evidence of cardiac tamponade, and persistent symptoms despite full anti-inflammatory therapies, adjunctive use of betablockers, if not contraindicated, can be helpful to improve symptom control by reducing heart rate and exacerbation of chest pain at higher heart rates [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of pericardial effusion is discussed separately. (See  <a class="medical medical_review" href="/d/html/143123.html" rel="external">"Pericardial effusion: Approach to management"</a>.)</p><p></p><p class="bulletIndent1">Patients with cardiac tamponade require urgent pericardial fluid removal. (See  <a class="medical medical_review" href="/d/html/4921.html" rel="external">"Cardiac tamponade"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of recurrent (or incessant) pericarditis is discussed separately. (See  <a class="medical medical_review" href="/d/html/4944.html" rel="external">"Recurrent pericarditis", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of constrictive pericarditis is discussed separately. (See  <a class="medical medical_review" href="/d/html/140886.html" rel="external">"Constrictive pericarditis: Management and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H12604901"><span class="h3">Pericardiectomy</span><span class="headingEndMark"> — </span>Surgical removal of all or part of the pericardium is virtually never required for the treatment of acute pericarditis. The role of pericardiectomy in patients with recurrent pericarditis is discussed separately. (See  <a class="medical medical_review" href="/d/html/4944.html" rel="external">"Recurrent pericarditis", section on 'Role of pericardiectomy'</a>.)</p><p class="headingAnchor" id="H1342044861"><span class="h2">Treatment in patients with chronic kidney disease</span><span class="headingEndMark"> — </span>Treatment for pericarditis in patients with advanced chronic kidney disease involves initiation or intensification of dialysis when uremia is the underlying cause, along with selective use of NSAIDs, <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>, and corticosteroids. Patients with uremic pericarditis who are not already receiving dialysis should initiate dialysis. In patients already receiving dialysis for over two months (dialysis-associated pericarditis), the dialysis prescription is usually intensified. However, the frequency of improvement in pericarditis in these patients is lower than in patients in whom dialysis was recently initiated, and medical therapies are often required. The approach to medical therapy is similar to patients without chronic kidney disease.</p><p class="headingAnchor" id="H3251375345"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Patients with acute idiopathic or viral pericarditis have a good long-term prognosis. Cardiac tamponade rarely occurs in patients with acute idiopathic pericarditis and is more common in patients with a specific underlying etiology such as malignancy, tuberculosis, or purulent pericarditis. Constrictive pericarditis may occur in approximately 1 percent of patients with acute idiopathic pericarditis and is also more common in patients with a specific etiology. (See  <a class="medical medical_review" href="/d/html/4938.html" rel="external">"Constrictive pericarditis: Diagnostic evaluation"</a>.)</p><p>Approximately 15 to 30 percent of patients with idiopathic acute pericarditis who are not treated with <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> develop either recurrent or incessant disease. Immune mechanisms appear to be of primary importance in the majority of cases, and the term "chronic autoreactive" pericarditis has been used. Risk factors for recurrent pericarditis include lack of response to NSAIDs, the need for corticosteroid therapy, and creation of a pericardial window. The pathogenesis, course, and treatment of recurrent pericarditis are discussed separately. (See  <a class="medical medical_review" href="/d/html/4944.html" rel="external">"Recurrent pericarditis"</a>.)</p><p>Sex may also predict the likelihood of complications. In a series of 453 consecutive cases of acute pericarditis, women were at increased risk of complications (hazard ratio 1.65, 95% CI 1.08-2.52) [<a href="#rid9">9</a>]. A possible explanation of this finding is the higher frequency of autoimmune etiologies (eg, connective tissue diseases) in women.</p><p class="headingAnchor" id="H3557792169"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116655.html" rel="external">"Society guideline links: Pericardial disease"</a>.)</p><p class="headingAnchor" id="H12602728"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16976.html" rel="external">"Patient education: Pericarditis in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/3427.html" rel="external">"Patient education: Pericarditis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H12602735"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for hospitalization</strong> – Patients with acute pericarditis with one or more high-risk markers (eg, fever, evidence of cardiac tamponade, immunosuppression, etc) should be admitted to the hospital in order to initiate appropriate therapy and expedite a thorough initial evaluation  (<a class="graphic graphic_algorithm graphicRef114845" href="/d/graphic/114845.html" rel="external">algorithm 1</a>). Conversely, patients with uncomplicated (ie, low-risk) acute pericarditis can usually be evaluated and sent home, with outpatient follow-up. (See <a class="local">'Which patients require hospitalization?'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial antiinflammatory therapy </strong> (<a class="graphic graphic_algorithm graphicRef114845" href="/d/graphic/114845.html" rel="external">algorithm 1</a>)<strong> </strong>(see <a class="local">'General approach to treatment'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General regimen</strong> – For nearly all patients with acute idiopathic or viral pericarditis, we recommend combination therapy with a nonsteroidal antiinflammatory drug (NSAID) plus <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> rather than an NSAIDs alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). This is based upon a reduced rate of recurrent pericarditis and a low incidence of side effects with colchicine  (<a class="graphic graphic_table graphicRef56484" href="/d/graphic/56484.html" rel="external">table 2</a>). We generally administer <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> or <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> plus colchicine. An acceptable alternative is <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> plus colchicine in cases that are poorly responsive to ibuprofen or aspirin. (See <a class="local">'Nonsteroidal antiinflammatory drugs'</a> above and <a class="local">'Colchicine'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Following acute myocardial infarction</strong> – In patients with acute pericarditis occurring within days following a myocardial infarction (MI), we suggest <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> plus <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>  (<a class="graphic graphic_table graphicRef56484" href="/d/graphic/56484.html" rel="external">table 2</a>) rather than another NSAID plus colchicine (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). These patients already have an indication to use aspirin at lower doses. Moreover, other NSAIDs may interfere with healing and scar formation. Glucocorticoids and NSAIDs other than aspirin should generally be <strong>AVOIDED</strong> in patients with acute pericarditis following an acute MI, but may be considered in those with persistent pericardial effusion not responding to aspirin and colchicine and with evidence of constrictive physiology and organization. (See <a class="local">'Nonsteroidal antiinflammatory drugs'</a> above and  <a class="medical medical_review" href="/d/html/4937.html" rel="external">"Pericardial complications of myocardial infarction", section on 'Management of PIP'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For patients with NSAID contraindications or a specific indication for glucocorticoid therapy</strong> –<strong> </strong>Glucocorticoids are used for initial treatment of acute pericarditis only in patients with contraindications to NSAIDs (eg, renal failure or pregnancy at ≥20 weeks gestation), or for specific indications (eg, systemic inflammatory diseases), and should be used at the lowest effective dose. The latter recommendation results from the greater likelihood of recurrent pericarditis when glucocorticoid therapy is used early in the course of the disease, along with a number of potentially significant side effects of systemic glucocorticoid therapy. (See <a class="local">'Glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent2">For patients who require glucocorticoid therapy for acute pericarditis, we suggest the use of moderate initial dosing (eg, 0.2 to 0.5 mg/kg/day of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>) followed by a slow taper rather than high doses with a rapid taper  (<a class="graphic graphic_table graphicRef56484" href="/d/graphic/56484.html" rel="external">table 2</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Our approach to glucocorticoid dosing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific therapy</strong> – In cases of pericarditis due to identifiable causes other than viral infection (eg, bacterial infection or malignancy), management is focused upon the underlying disorder and, if necessary, drainage of an associated pericardial effusion. (See <a class="local">'Adjunctive therapies'</a> above and <a class="local">'General approach to treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Activity restriction</strong> – Strenuous physical activity may trigger recurrence of symptoms; therefore, such activity should be avoided until symptom resolution and normalization of biomarkers. (See <a class="local">'Activity restriction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive therapies</strong> – Most patients with uncomplicated low risk acute pericarditis are managed effectively with medical therapy alone. Patients with one or more of the following clinical features may require adjunctive therapies such as pericardial drainage or pericardiectomy: a moderate or large pericardial effusion (particularly if hemodynamically significant and causing cardiac tamponade or suspicion of a neoplastic or bacterial etiology), frequent highly symptomatic recurrences of acute pericarditis with pericardial effusion, or the late development of constrictive pericarditis. Beta blockers may be considered for those with symptoms despite full antiinflammatory therapies and high heart rates (eg, heart rate &gt;70 to 75 beats per minute at rest) to achieve better and faster control of symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Patients with acute idiopathic or viral pericarditis generally have a good long-term prognosis. Cardiac tamponade and late constrictive pericarditis rarely occur in patients with acute idiopathic pericarditis. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Imazio M, Spodick DH, Brucato A, et al. Controversial issues in the management of pericardial diseases. Circulation 2010; 121:916.</a></li><li><a class="nounderline abstract_t">Imazio M, Brucato A, Derosa FG, et al. Aetiological diagnosis in acute and recurrent pericarditis: when and how. J Cardiovasc Med (Hagerstown) 2009; 10:217.</a></li><li><a class="nounderline abstract_t">Imazio M, Brucato A, Mayosi BM, et al. Medical therapy of pericardial diseases: part I: idiopathic and infectious pericarditis. J Cardiovasc Med (Hagerstown) 2010; 11:712.</a></li><li><a class="nounderline abstract_t">Imazio M, Brucato A, Mayosi BM, et al. Medical therapy of pericardial diseases: part II: Noninfectious pericarditis, pericardial effusion and constrictive pericarditis. J Cardiovasc Med (Hagerstown) 2010; 11:785.</a></li><li><a class="nounderline abstract_t">Imazio M, Gaita F, LeWinter M. Evaluation and Treatment of Pericarditis: A Systematic Review. JAMA 2015; 314:1498.</a></li><li><a class="nounderline abstract_t">Permanyer-Miralda G, Sagristá-Sauleda J, Soler-Soler J. Primary acute pericardial disease: a prospective series of 231 consecutive patients. Am J Cardiol 1985; 56:623.</a></li><li><a class="nounderline abstract_t">Zayas R, Anguita M, Torres F, et al. Incidence of specific etiology and role of methods for specific etiologic diagnosis of primary acute pericarditis. Am J Cardiol 1995; 75:378.</a></li><li><a class="nounderline abstract_t">Imazio M, Demichelis B, Parrini I, et al. Day-hospital treatment of acute pericarditis: a management program for outpatient therapy. J Am Coll Cardiol 2004; 43:1042.</a></li><li><a class="nounderline abstract_t">Imazio M, Cecchi E, Demichelis B, et al. Indicators of poor prognosis of acute pericarditis. Circulation 2007; 115:2739.</a></li><li><a class="nounderline abstract_t">Pelliccia A, Solberg EE, Papadakis M, et al. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J 2019; 40:19.</a></li><li><a class="nounderline abstract_t">Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015; 36:2921.</a></li><li><a class="nounderline abstract_t">Imazio M, Brucato A, Maestroni S, et al. Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation 2011; 123:1092.</a></li><li><a class="nounderline abstract_t">Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation 2005; 112:2012.</a></li><li><a class="nounderline abstract_t">Arunasalam S, Siegel RJ. Rapid resolution of symptomatic acute pericarditis with ketorolac tromethamine: a parenteral nonsteroidal antiinflammatory agent. Am Heart J 1993; 125:1455.</a></li><li><a class="nounderline abstract_t">Spodick DH. Acute pericarditis: current concepts and practice. JAMA 2003; 289:1150.</a></li><li><a class="nounderline abstract_t">McGinn JT, Rosati M, McGinn TG. Indomethacin in treatment of pericarditis. N Y State J Med 1970; 70:1783.</a></li><li><a class="nounderline abstract_t">Berman J, Haffajee CI, Alpert JS. Therapy of symptomatic pericarditis after myocardial infarction: retrospective and prospective studies of aspirin, indomethacin, prednisone, and spontaneous resolution. Am Heart J 1981; 101:750.</a></li><li><a class="nounderline abstract_t">Imazio M, Trinchero R. Clinical management of acute pericardial disease: a review of results and outcomes. Ital Heart J 2004; 5:803.</a></li><li><a class="nounderline abstract_t">Hammerman H, Alker KJ, Schoen FJ, Kloner RA. Morphologic and functional effects of piroxicam on myocardial scar formation after coronary occlusion in dogs. Am J Cardiol 1984; 53:604.</a></li><li><a class="nounderline abstract_t">Imazio M, Trinchero R. Triage and management of acute pericarditis. Int J Cardiol 2007; 118:286.</a></li><li><a class="nounderline abstract_t">Imazio M, Cecchi E, Demichelis B, et al. Myopericarditis versus viral or idiopathic acute pericarditis. Heart 2008; 94:498.</a></li><li><a class="nounderline abstract_t">Imazio M, Brucato A, Trinchero R, et al. Colchicine for pericarditis: hype or hope? Eur Heart J 2009; 30:532.</a></li><li><a class="nounderline abstract_t">Imazio M. Contemporary management of pericardial diseases. Curr Opin Cardiol 2012; 27:308.</a></li><li><a class="nounderline abstract_t">Imazio M, Brucato A, Cemin R, et al. A randomized trial of colchicine for acute pericarditis. N Engl J Med 2013; 369:1522.</a></li><li><a class="nounderline abstract_t">Sambola A, Roca Luque I, Mercé J, et al. Colchicine Administered in the First Episode of Acute Idiopathic Pericarditis: A Randomized Multicenter Open-label Study. Rev Esp Cardiol (Engl Ed) 2019; 72:709.</a></li><li><a class="nounderline abstract_t">Imazio M. Why Colchicine Should Continue To Be The First Line Therapy For Acute And Recurrent Pericarditis. Rev Esp Cardiol (Engl Ed) 2019; 72:705.</a></li><li><a class="nounderline abstract_t">Imazio M, Brucato A, Forno D, et al. Efficacy and safety of colchicine for pericarditis prevention. Systematic review and meta-analysis. Heart 2012; 98:1078.</a></li><li><a class="nounderline abstract_t">Alabed S, Cabello JB, Irving GJ, et al. Colchicine for pericarditis. Cochrane Database Syst Rev 2014; :CD010652.</a></li><li><a class="nounderline abstract_t">Imazio M, Brucato A, Belli R, et al. Colchicine for the prevention of pericarditis: what we know and what we do not know in 2014 - systematic review and meta-analysis. J Cardiovasc Med (Hagerstown) 2014; 15:840.</a></li><li><a class="nounderline abstract_t">Melendo-Viu M, Marchán-Lopez Á, Guarch CJ, et al. A systematic review and meta-analysis of randomized controlled trials evaluating pharmacologic therapies for acute and recurrent pericarditis. Trends Cardiovasc Med 2023; 33:319.</a></li><li><a class="nounderline abstract_t">Lange RA, Hillis LD. Clinical practice. Acute pericarditis. N Engl J Med 2004; 351:2195.</a></li><li><a class="nounderline abstract_t">Shabetai R. Often neglected yet important: the pericardium and its diseases. Herz 2000; 25:717.</a></li><li><a class="nounderline abstract_t">Imazio M, Demichelis B, Parrini I, et al. Recurrent pain without objective evidence of disease in patients with previous idiopathic or viral acute pericarditis. Am J Cardiol 2004; 94:973.</a></li><li><a class="nounderline abstract_t">Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med 2005; 165:1987.</a></li><li><a class="nounderline abstract_t">Artom G, Koren-Morag N, Spodick DH, et al. Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis. Eur Heart J 2005; 26:723.</a></li><li><a class="nounderline abstract_t">Imazio M, Demichelis B, Parrini I, et al. Management, risk factors, and outcomes in recurrent pericarditis. Am J Cardiol 2005; 96:736.</a></li><li><a class="nounderline abstract_t">Lotrionte M, Biondi-Zoccai G, Imazio M, et al. International collaborative systematic review of controlled clinical trials on pharmacologic treatments for acute pericarditis and its recurrences. Am Heart J 2010; 160:662.</a></li><li><a class="nounderline abstract_t">Imazio M, Brucato A, Cumetti D, et al. Corticosteroids for recurrent pericarditis: high versus low doses: a nonrandomized observation. Circulation 2008; 118:667.</a></li><li><a class="nounderline abstract_t">Imazio M, Andreis A, Agosti A, et al. Usefulness of Beta-Blockers to Control Symptoms in Patients With Pericarditis. Am J Cardiol 2021; 146:115.</a></li></ol></div><div id="topicVersionRevision">Topic 15800 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20177006" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Controversial issues in the management of pericardial diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19262208" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Aetiological diagnosis in acute and recurrent pericarditis: when and how.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20736783" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Medical therapy of pericardial diseases: part I: idiopathic and infectious pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20925146" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Medical therapy of pericardial diseases: part II: Noninfectious pericarditis, pericardial effusion and constrictive pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26461998" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Evaluation and Treatment of Pericarditis: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4050698" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Primary acute pericardial disease: a prospective series of 231 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7856532" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Incidence of specific etiology and role of methods for specific etiologic diagnosis of primary acute pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15028364" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Day-hospital treatment of acute pericarditis: a management program for outpatient therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17502574" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Indicators of poor prognosis of acute pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30561613" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26320112" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21357824" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: implications for the diagnosis, therapy, and prognosis of pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16186437" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8480612" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Rapid resolution of symptomatic acute pericarditis with ketorolac tromethamine: a parenteral nonsteroidal antiinflammatory agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12622586" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Acute pericarditis: current concepts and practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5270249" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Indomethacin in treatment of pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7234652" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Therapy of symptomatic pericarditis after myocardial infarction: retrospective and prospective studies of aspirin, indomethacin, prednisone, and spontaneous resolution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15633435" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical management of acute pericardial disease: a review of results and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6695791" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Morphologic and functional effects of piroxicam on myocardial scar formation after coronary occlusion in dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17049636" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Triage and management of acute pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17575329" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Myopericarditis versus viral or idiopathic acute pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19190012" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Colchicine for pericarditis: hype or hope?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22450720" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Contemporary management of pericardial diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23992557" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A randomized trial of colchicine for acute pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30683494" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Colchicine Administered in the First Episode of Acute Idiopathic Pericarditis: A Randomized Multicenter Open-label Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31175067" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Why Colchicine Should Continue To Be The First Line Therapy For Acute And Recurrent Pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22442198" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Efficacy and safety of colchicine for pericarditis prevention. Systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25164988" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Colchicine for pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25000255" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Colchicine for the prevention of pericarditis: what we know and what we do not know in 2014 - systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35131416" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A systematic review and meta-analysis of randomized controlled trials evaluating pharmacologic therapies for acute and recurrent pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15548780" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical practice. Acute pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11200117" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Often neglected yet important: the pericardium and its diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15464694" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Recurrent pain without objective evidence of disease in patients with previous idiopathic or viral acute pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16186468" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15755753" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16125506" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Management, risk factors, and outcomes in recurrent pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20934560" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : International collaborative systematic review of controlled clinical trials on pharmacologic treatments for acute pericarditis and its recurrences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18645054" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Corticosteroids for recurrent pericarditis: high versus low doses: a nonrandomized observation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33539856" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Usefulness of Beta-Blockers to Control Symptoms in Patients With Pericarditis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
